Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab ® ) in pre-exposure prophylaxis in humans Background: A WHO experts committee recommended the substitution of antirabic vaccines produced in nervous tissue, by vaccines produced in tissue cultures.Aim: To compare the immunogenic capacity of antirabic vaccines CRL (produced in nervous tissue) and Verorab ® (produced in tissue culture), used for pre-exposure prophylaxis in humans.Patients and methods: Fifty four volunteers were immunized for this study.The first group, vaccinated with CLR was treated with a scheme of 4 subcutaneous peri umbilical doses in days 0, 3, 7 and 28.The second group, vaccinated with Verorab ® vaccine was treated with a scheme of 3 intramuscular doses in deltoid zone at days 0, 7 and 28.Blood samples were obtained at days 0, 7, 42 and 365 to measure neutralizing antibodies using the Inhibition of Fluorescent Focus Technique (RFFIT).Results: At day seven, a primary non protective immunologic response was observed in both groups, with titers significantly higher in the group vaccinated with Verorab ® .At day 42, no differences were observed.At day 365, all subjects vaccinated with Verorab ® and 50% of individuals vaccinated with CRL had protective antibody titers (p <0,05).Conclusions: The vaccine produced in cell breeds (Verorab ® ) produces a better an faster immunologic response compared to the CRL vaccine (Rev Méd Chile 2004; 132: 41-6).